



Contents lists available at [SciVerse ScienceDirect](#)

NeuroToxicology



Modeling the binding mechanism of Alzheimer's $A\beta_{1-42}$ to nicotinic acetylcholine receptors based on similarity with snake α -neurotoxins[☆]

Noa Maatuk, Abraham O. Samson^{*}

Faculty of Medicine, Bar-Ilan University, Safed 14302, Israel

ARTICLE INFO

Article history:

Received 12 July 2012

Accepted 14 September 2012

Available online xxx

Keywords:

Alzheimer's disease

Amyloid

$A\beta_{1-42}$

α -Neurotoxin

Snake toxin

Bungarotoxin

Atratoxin

Acetylcholine receptor

Nicotinic acetylcholine receptor

ABSTRACT

For over a decade, it has been known that amyloid β ($A\beta$) peptides of Alzheimer's disease bind to the nicotinic $\alpha 7$ acetylcholine receptor (AChR) with picomolar affinity, and that snake α -neurotoxins competitively inhibit this binding. Here we propose a model of the binding mechanism of $A\beta$ peptides to $\alpha 7$ -AChR at atomic level. The binding mechanism is based on sequence and structure similarities of $A\beta$ residues with functional residues of snake α -neurotoxins (ATX) in complex with AChR. The binding mechanism involves residue $A\beta K28$ (similar to $ATX R32$) which forms cation/ π interactions in the acetylcholine binding site, and residues $A\beta G29$ – $A\beta I32$ [GAIL] (similar to $ATX G33$ – $ATX I36$ [GTII]) which form an intermolecular β -sheet with residues $\alpha 7 F189$ – $\alpha 7 E191$ of AChR. Through these interactions, we propose that the AChR serves as a chaperone for $A\beta$ conformational changes from α - to β -hairpin. The interactions which block channel opening provide fundamental insight into $A\beta$ neurotoxicity and cognition impairment, that could contribute to pathogenic processes in Alzheimer's disease, thus paving the way for structure based therapies.

© 2012 Elsevier Inc. All rights reserved.

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of proteins and protein fragments in the brain, progressive neuronal loss, inflammation, and the gradual and inevitable decline of memory and cognition. Much effort has been invested in finding a cure for the disease and understanding its causative origins. Major milestones include the isolation of amyloid β peptides from plaques, and the demonstration of abnormal tau phosphorylation in tangles. These milestones have led to the amyloid hypothesis proposing that amyloid fibrils and plaques in the brain were the drivers of the disease, while more recent versions of the hypothesis suggest small soluble aggregates of $A\beta$ peptides as the primary impetus of disease progression.

Amyloid β peptides ($A\beta$) are derived from the Amyloid Precursor Protein (APP) through sequential cleavage by various

proteolytic enzymes such as aspartyl protease, β -secretase and presenilin-dependent β -secretase (De Strooper, 2000). $A\beta$ vary in length up to 42 amino acid residues and bind to neuronal $\alpha 7$ -AChR with pico- to femtomolar affinity (Wang et al., 2000a,b). This binding leads to intraneuronal accumulation of complexes between $\alpha 7$ -AChR and $A\beta_{1-42}$ (Nagele et al., 2002), blocking of $\alpha 7$ -AChR channels (Liu et al., 2001), cholinergic neurotransmission defects (Lee and Wang, 2003), $A\beta$ fibrillization as well as fast tau phosphorylation (Wang et al., 2003), and eventually neuronal cell death (Wang et al., 2000a), all contributing to the progression of Alzheimer's disease. Importantly, the exact binding mechanism between AChR and $A\beta_{1-42}$ is unknown to date and to our knowledge no molecular model has been proposed so far. $A\beta$ fibrillization involves formation of dimers and small oligomers followed by growth into protofibrils and fibrils via a complex multistep-nucleated polymerization that eventually forms $A\beta$ plaques or deposits (De Strooper, 2000). The events leading up to polymerization, and in particular the initial nucleation and conversion of $A\beta$ remains elusive in spite of recent molecular dynamics (MD) studies (Straub and Thirumalai, 2011).

Nicotinic acetylcholine receptors (AChR) are a family of ligand-gated pentameric ion channels (Lindstrom, 1995; Le Novere and Changeux, 1995; Dajas-Bailador and Wonnacott, 2004; Kalamida et al., 2007). The main function of the AChR family is to transmit signals of the neurotransmitter acetylcholine at neuromuscular junctions and in the central and peripheral nervous systems (Steinlein, 1998). To date, 17 different subunits ($\alpha 1$ – $\alpha 10$, $\beta 1$ – $\beta 4$, δ , ϵ ,

[☆] This research was supported by the Katz foundation and Marie-Curie CIG grant 322113 to AS.

Abbreviations: AChR, acetylcholine receptor; α AChR, acetylcholine receptor α -subunit; AD, Alzheimer's disease; $A\beta$, amyloid β ; $A\beta_{1-42}$, 42 amino acid amyloid β peptide, DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA; $A\beta_{1-40}$, same as $A\beta_{1-42}$ without two last residues, IA; $A\beta X$, amino acid residues of amyloid β ; $BTX X$, residues of α -bungarotoxin (PDB ID 1L4W), representing long α -neurotoxin; $ATX X$, residues of atratoxin (PDB ID 1VB0), representing short α -neurotoxins; $\alpha 7 X$, residues of the AChR are indicated with a superscript $\alpha 1$, $\alpha 7$, γ , or δ distinctive of the subunit type.

^{*} Corresponding author at: School of Medicine, Stanford University, Stanford, CA 94305, USA. Tel.: +1 972 54 7958894.

E-mail address: avraham.samson@stanford.edu (A.O. Samson).

γ) have been identified in human which can combine to generate many subtypes of homo- and heteropentameric AChR with different physiologies, pharmacologies, and anatomical distributions (Lindstrom, 1995; Le Novere and Changeux, 1995; Dajas-Bailador and Wonnacott, 2004; Kalamida et al., 2007). Two major subtypes exist in the brain, namely those comprised of $\alpha 7$ and those consisting of $\alpha 4\beta 2$. AChR also bind a variety of agonists such as nicotine, cytisine and epibatidine, and antagonists such as α -tubocurarine, lophotoxins, β peptides, and last but not least snake α -neurotoxins.

α -Neurotoxins derived from snake venom bind to AChR and competitively inhibit acetylcholine binding, thereby preventing the depolarizing action on postsynaptic membranes, and blocking neuronal transmission (Samson et al., 2002). α -Neurotoxins are divided into two groups according to their length, namely short α -neurotoxins such as atratoxin (ATX) comprising 61 residues, and long α -neurotoxins such as α -bungarotoxin (BTX) consisting of 74 amino acids. The binding mechanism of BTX to AChR was determined in our group using NMR spectroscopy at atomic level (Samson et al., 2002). In that study, we showed how BTX fits snugly into the acetylcholine binding site of AChR thereby blocking neuronal transmission.

In this study, we show that A β ₁₋₄₂ and α -neurotoxins share surprising sequence and structural similarities. To our knowledge this is the first report of such similarities between α -neurotoxins and A β ₁₋₄₂. The similarities are pronounced largely in functional residues of α -neurotoxins that bind the AChR. Based on the similarities and interactions of BTX with α 1-AChR we propose a binding mechanism of A β ₁₋₄₂ to α 7-AChR. To the best of our information, this is the first publication of a molecular model of A β ₁₋₄₂ in complex with α 7-AChR. The model may also serve as a template for the interaction of A β peptides with other neuronal AChR subtypes such as the α β ₂, and α γ β ₂ pentamers. Finally, we suggest that AChR interactions stabilize A β refolding into β -rich structures. These interactions which inhibit AChR provide novel insight into Alzheimer's disease and pave the way for designing potential therapeutic drugs capable of disrupting A β ₁₋₄₂ interactions with AChR.

1. Materials and methods

1.1. Sequence alignment and homology modeling

The sequence of Aβ_{1–42} was aligned with those of short and long α-neurotoxins obtained from the Uniprot databank (<http://www.uniprot.org/>) using the ClustalW multiple sequence alignment tool with default values (Thompson et al., 1994). Similarly,

the acetylcholine binding protein (AChBP) sequence was aligned with those of $\alpha 1$, $\alpha 7$, β , γ , and δ subunits of the AChR.

Our $\alpha 7$ -AChR model was based on the structure of AChBP (PDB ID 1I9B (Brejc et al., 2001)). Since single AChBP subunits consist of 210 amino acids, the $\alpha 7$ subunits were delimited to this size. The $\alpha 7$ -AChR was assumed to be a homopentamer. For most of the sequence, the alignment was straightforward requiring no insertion or deletions. Such segments were considered structurally conserved regions, in which the conformation of the polypeptide chain is unchanged. Random loops were generated where insertion or deletions occurred, using Pymol. No backbone-backbone clashes were observed. Side chains exhibiting steric clashes with other side chain or backbone atoms were manually assigned with an alternative rotamer conformation using Pymol.

The model of $\alpha\beta_{1-42}$ in long α -neurotoxin conformation was based on the structure of BTX (PDB ID 1L4W) (residues of α -bungarotoxin; representing long α -neurotoxin, are indicated with a superscript BTX (^{BTX}X)). Since the homology with $\alpha\beta_{1-42}$ is pronounced particularly in finger II of the toxin, the model was delimited to this region. The modeling process was similar to that of $\alpha 7$ -AChR.

1.2. Docking

To dock five $\text{A}\beta_{1-42}$ molecules into the $\alpha 7$ -AChR model, the structure of $\alpha 1$ -AChR in complex with BTX (PDB ID 1LK1 ([Samson et al., 2002](#))) was used as a template. Structurally conserved regions of $\alpha 7$ -AChR were superimposed onto those of $\alpha 1$ -AChR, and residues $^{\text{AB}}\text{K28}$ - $^{\text{AB}}\text{I32}$ of $\text{A}\beta_{1-42}$ were superimposed onto residues $^{\text{BTX}}\text{R36}$ - $^{\text{BTX}}\text{V40}$ of BTX.

1.3. PDB structure search

To find PDB structures with glycine repeats, the Protein Segment Finder (PSF) search engine was used (Samson and Levitt, 2009).

2. Results

2.1. Alzheimer's A β_{1-42} sequence and structure is similar to snake α -neurotoxins

The sequence alignment of long α -neurotoxins and A β ₁₋₄₂ is shown in Table 1. The sequence similarity is pronounced principally in functional regions of the toxin that bind AChR, namely finger II residues ^{BTX}W28 (A β F20), ^{BTX}D30 (A β E22), and ^{BTX}R36-^{BTX}L42 (A β K28-A β L34). Of particular interest are the

Table 1
Multiple sequence alignment of Alzheimer's A β_{1-42} and long snake α -neurotoxins. Shown are the sequences of α -neurotoxins named according to their UniProt accession ID and of A β_{1-42} . The alignment was performed using ClustalW multiple sequence alignment (Thompson et al., 1994). Identical residues are marked with asterisks (*), conserved residues with double dots (:), and semi-conserved residues with single dots (.). Note the sequence similarity of A β F19-A β L34 and B α T α M27-B α T α L42 (highlighted in gray) which are both known to adopt β -hairpin conformations. Of special interest, is the similarity of A β K28-A β I33 and B α T α R36-B α T α V40 (highlighted in black) which in the latter form multiple interactions with the acetylcholine receptor.

```

---Finger I---          ---Finger II---          ---Finger III---          ---Tail---
D2N121  IVCHTTATSPISAVTCPPGENLCYRKMWCDAFCSSRCKVVELGCAATCPSKKPYEEVTCCSTDKCNPHPKQRPQ-74
D2N122  IVCHTTATSPISAVTCPPGENLCYRKMWCDALCSSRCKVVELGCAATCPSKKPYEEVTCCSTDKCNPHPKQRPQ-74
P60616  IVCHTTATSPISAVTCPPGENLCYRKMWCDVFCSSRCKVVELGCAATCPSKKPYEEVTCCSTDKCNPHPKQRPQ-74
D2N117  IVCHATATSPISAVTCPPGENLCYRKMWCDAFCSSRCKVVELGCAATCPSKKPYEEVTCCSTDKCNPHPKQRPQ-74
D2N120  IVCHTTATSPISAVTCPPGENLCYRKMWCDAFCSSRCKVVELGCAATCPSKKPYEEVTCCSTDKCNPHPKQRPQ-74
D2N116  LLCCHTSPISISTVTPCSPGENLCYTKMWCDAFCSSRCKVIELGCVATCPQPKPYEEVTCCSTDKCNPHPKQRPQ-74
A1IVR8  LLCYKTP-SPINAETCPPGENLCYTKMWCDAWCSSRCKVIELGCAATCPSKKPYEEVTCCSTDKCNPHPKQRPQ-73
C5ILC5  LLCYKTP-SPINAETCPPGENLCYTKMWCDAWCSSRCKVIELGCAATCPSKKPYEEVDCSTDKCNPHPKLRP-72
A1IVR7  LLCYKTP-SPINAETCPPGENLCYTKMWCDAWCSSRCKVVELGCAATCPSKKPYEEVTCSTDKCNPHPKQRPD-73
A1IVR9  LLCYKTP-IPINAETCPPGENLCYTKMWCDIWCSSRCKVVELGCAATCPSKKPYEEVTCCSTDKCNPHPKQRPD-73
P34073  VICYRKYT--NNVKTCPDGENVCYTKMWCDGFCTSRCKVVELGCAATCPIRKPQNEVKCCSTNKCNPHPKRKKRPP-74
Aβ1-42  -----DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-----42

```

Table 2

Multiple sequence alignment of Alzheimer's $A\beta_{1-42}$ and short snake α -neurotoxins. Shown are the sequences of α -neurotoxins named according to their UniProt accession ID and of $A\beta_{1-42}$. The alignment was performed using ClustalW multiple sequence alignment (Thompson et al., 1994). Identical residues are marked with asterisks (*), conserved residues with double dots (:), and semi-conserved residues with single dots (.). Note the sequence similarity of $A\beta_{1-42}$ and ATX_{136} of short α -neurotoxins (highlighted in gray) which are both known to adopt β -hairpin conformations. Of special interest, is the similarity of $A\beta_{1-42}$ and ATX_{136} (highlighted in black) which in the latter forms multiple interactions with the acetylcholine receptor.

	-Finger I-	----Finger II----	Finger III	-Tail-	
P01427	LECHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P59275	LECHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P59276	LECHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P60773	LECHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P60772	LECHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P60774	LECHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P01426	LECHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P01425	LECHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P01424	MECHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P34075	KTCYNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P01422	MICHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P01423	MICHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P25675	MICHNQSSQPTTKTCSGETN	YKQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P01420	MICYKQSLQFPITTVCPGEKNCY	KQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
P01421	MICYKQSLQFPITTVCPGEKNCY	KQWSDHRTII	ERGCGCPKVKPGVNLNCCRTDRCNN		61
$A\beta_{1-42}$	DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA				42
	.	:	:	:	:

similarity of residue BTX_{R36} ($A\beta_{K28}$), located on the tip of finger II, which inserts into the acetylcholine binding site (Samson et al., 2002), the similarity of residues BTX_{V39} ($A\beta_{I31}$), BTX_{V40} ($A\beta_{I32}$), BTX_{L42} ($A\beta_{I34}$) which form an intermolecular β -sheet with residues α^1Y189 and α^1Y190 of the AChR, and the similarity of BTX_{G37} ($A\beta_{G29}$) which serves as a small flexible spacer. Also similar, are residues at the base of finger II, such as BTX_{W28} ($A\beta_{F20}$) and BTX_{D30} ($A\beta_{E22}$) which form multiple interactions with γ or δ subunits of AChR (Samson et al., 2002). This double register motif is typical of β -sheets interacting through one face only. Conveniently, the disulfide bound cysteine residues BTX_{C29} and BTX_{C33} , at the tip of finger II, are replaced by $A\beta_{A21}$ and $A\beta_{G25}$ in the amyloid β -hairpin that allow the residue backbones to come equidistantly close. Finally, both finger II of α -neurotoxins (Samson et al., 2002) and $A\beta_{1-42}$ (Hoyer et al., 2008) adopt a similar β -hairpin conformation with backbone RMSD values of 1.27 Å for the segment BTX_{W28} – BTX_{L42} ($A\beta_{F20}$ – $A\beta_{I34}$). Overall, the sequence and structure similarity of long α -neurotoxin finger II and $A\beta_{1-42}$ is impressive as it is surprising.

Also striking is the $A\beta_{1-42}$ sequence similarity with short α -neurotoxins shown in Table 2. As with long α -neurotoxins, the similarity is especially pronounced in functional regions that interact with AChR, namely finger II residues ATX_{Y24} ($A\beta_{F20}$), ATX_{K26} ($A\beta_{E22}$), ATX_{F28} ($A\beta_{V24}$), ATX_{S30} ($A\beta_{S26}$), and ATX_{R32} – ATX_{I36} ($A\beta_{K28}$ – $A\beta_{I32}$). Strikingly, $A\beta_{1-42}$ sequence $A\beta_{K28}$ – $A\beta_{I32}$ (KGAI) is highly similar to finger II sequence ATX_{R32} – ATX_{I36} (RGTH) which interacts with the α -subunit of AChR (Samson et al., 2002). Interestingly, residues at the base of finger II namely ATX_{Y24} ($A\beta_{F20}$), and ATX_{K26} ($A\beta_{E22}$), ATX_{F28} ($A\beta_{V24}$), ATX_{S30} ($A\beta_{S26}$), display a double register motif, typical of β -sheets interacting with one face only like ATX in complex with AChR. Finally, both finger II of α -neurotoxins (Samson et al., 2002) and $A\beta_{1-42}$ (Hoyer et al., 2008) adopt a similar β -hairpin conformation with backbone RMSD values of 1.79 Å for the segment ATX_{W27} – ATX_{I36} ($A\beta_{D23}$ – $A\beta_{I32}$). On the whole, the sequence and structure similarity of short α -neurotoxin finger II and $A\beta_{1-42}$ is remarkable as it is unexpected.

2.2. Binding mechanism of $A\beta_{1-42}$ to AChR

Based on sequence similarity of $A\beta_{1-42}$ and α -neurotoxins and the experimental finding that BTX competitively inhibits $A\beta_{1-42}$

binding to AChR (Wang et al., 2000a), there is strong evidence that binding to AChR occurs in the same site and through similar interactions. Shown in Figs. 1 and 2 are the secondary structures of $A\beta_{1-42}$ interacting with $\alpha 7$ -AChR, based on those of ATX and BTX. In both cases, $A\beta_{1-42}$ folds into a β -hairpin in which residues $A\beta_{A30}$ – $A\beta_{I32}$ form an intermolecular β -sheet with α^7F189 – α^7E191 . In the long toxin conformation (Fig. 1), $A\beta_{1-42}$ β -hairpin strands $A\beta_{F20}$ – $A\beta_{D23}$ are opposite $A\beta_{K28}$ – $A\beta_{I31}$ according to the alignment with BTX finger II. In the short toxin conformation (Fig. 2), $A\beta_{1-42}$ hairpin strands $A\beta_{E22}$ – $A\beta_{S26}$ are opposite $A\beta_{G29}$ – $A\beta_{G33}$ according to the alignment with ATX finger II. The short toxin sequence similarity of $A\beta$ (Fig. 2) is more remarkable than that of the long




Fig. 1. Secondary structure of long α -neurotoxins and $A\beta_{1-42}$ interacting with AChR. Shown on top is the secondary structure of BTX (PDB ID 1L4W) (in black) in complex with $\alpha 1$ -AChR (in red) (Samson et al., 2002). Shown on the bottom is the predicted secondary structure of $A\beta_{1-42}$ (in black) in complex with $\alpha 7$ -AChR (in red). The figure was prepared using ChemSketch.




Fig. 2. Secondary structure of short α -neurotoxins and A β ₁₋₄₂ interacting with AChR. Shown on top is the secondary structure of ATX (PDB ID 1VB0 (Lou et al., 2004)) (in black) in complex with α 7-AChR (in red) (Samson et al., 2002). Shown on the bottom is the predicted secondary structure of A β ₁₋₄₂ (in black) in complex with α 7-AChR (in red). The figure was prepared using ChemSketch.

toxin (Fig. 1), as there are more similarities. The two conformations do not preclude one another, and equilibrium between the two states through a β -hairpin register shift is thinkable. This register shift could lead to more than two conformations with different β -strand pairings like that of PDB IDs 20TK and 2BEG. In all conformations, the intermolecular β -sheet register does not shift, and residues A β ₂₉-A β ₃₀-A β ₃₁ remain opposite residues α ⁷F189- α ⁷Y190- α ⁷E191 alike short and long neurotoxins. The various A β conformations could exhibit different binding constants and toxicity to the AChR, thus accounting for the affinity controversies in the literature (Wang et al., 2000a). Also important

Table 3
Interactions between A β ₁₋₄₂ and α 7-acetylcholine receptor.

A β ₁₋₄₂	α 7-Subunit of AChR
E22	Y190
D23	E211
V24	Y190
G25	G189
S26	W77 Y190
N27	L37 S38 L39 W77 Q79 L141
K28	W77 Q79 L141 Y115 W171 Y190 Y217
G29	Y190 E191
A30	Y190 E191
I31	F189 Y191 E191
I32	F189 Y190 E191 C192
G33	S188
L34	F189

is the length of the amyloid peptide (i.e. A β ₁₋₄₀ and A β ₁₋₄₂) which could influences the secondary structure and composition of ADDL. These issues should be addressed experimentally for higher certainty, and such investigations are currently underway in our laboratory.

A homology derived model of human homopentameric α 7-AChR in complex with five A β ₁₋₄₂ molecules in long α -neurotoxin conformation is shown in Fig. 3. The model is based on the NMR structure of α 1-AChR in complex with two BTX molecules (PDB ID 1LK1 (Samson et al., 2002)). The difference in ligand stoichiometry arises from the fact that α 1-AChR has two ligand binding sites (2 α -subunits) whereas α 7-AChR has five of them (5 α -subunits). Other neuronal combinations of AChR subunits, such as the heteropentameric α 4 β 2, and α 7 β 2 have also been reported, and A β binding is expected to occur in a similar fashion at the α -subunit. We constricted our AChR model to the homopentameric α 7 form as it was shown experimentally to bind amyloid peptides. The A β ₁₋₄₂ hairpin forms multiple interactions with the α 7-AChR ligand binding site, all summarized in Table 3. Most notable of the interactions is that of A β _{K28} which inserts into the acetylcholine binding site and forms cation/ π interactions with aromatic




Fig. 3. Models of AChR in complex with snake α -neurotoxins and Alzheimer's A β ₁₋₄₂. Shown are top and side views of models of (A) α 1-AChR in complex with BTX (PDB ID 1LK1 (Samson et al., 2002)) and (B) human α 7-AChR in complex with A β ₁₋₄₂. The latter model is based on the former, by superimposing α 7-AChR residues α ⁷Y210- α ⁷C212 onto α 1-AChR residues α ⁷Y190- α ⁷C192, and A β ₁₋₄₂ residues A β _{G29}-A β _{I32} onto BTX residues BTX_{G37}-BTX_{V40}. Only A β ₁₋₄₂ residues A β _{H14}-A β _{G36} are shown. The figure was prepared using Pymol.

residues α^7 W77, α^7 Y115, α^7 W171, α^7 Y210 and α^7 Y217 paving the binding site (Fig. 4). In this fashion, $A\beta$ K28 sterically occludes acetylcholine binding, and blocks channel opening. This interaction is homologous to that formed by $^{BTX}R36$ in the ligand binding site of AChR (Samson et al., 2002). Interestingly, lysine (i.e. $A\beta$ K28), acetylcholine, and arginine ($^{BTX}R36$) are capable of mimicking each other since they possess a positively charged ammonium head linked through an aliphatic chain to a carbonyl tail (Fig. 4). Also notable is the antiparallel intermolecular β -sheet formed between $A\beta_{1-42}$ residues $A\beta$ A30– $A\beta$ I32 and AChR residues α^7 F189– α^7 E191 which accounts for the picomolar affinity (Wang et al., 2000a). This intermolecular β -sheet is homologous to that formed between BTX residues $^{BTX}K38$ – $^{BTX}V40$ and AChR residues α^1 Y189– α^1 T191 (Samson et al., 2002).

3. Discussion

3.1. Refolding of $A\beta_{1-42}$ is stabilized by AChR

The structure of native and free $A\beta$ is α -helical (i.e. PDB IDs 1IYT, 1BA4, 2LFM, 1AML, etc.) while that of fibrillar $A\beta$ is in β -hairpin conformation. Interestingly, most of the native structures show a kink in the helical structure around residue $A\beta$ K28 (Fig. 5). This helix breaking kink is intrinsic in all $A\beta$, and probably serves as a starting point for conformational transition from α - to β -structure. Once bound to the AChR, $A\beta$ is stabilized in its refolded β -hairpin conformation through an semi-induced fit mechanism involving antiparallel intermolecular β -sheet interactions with AChR (Fig. 5). Conveniently, the helix breaking kink is located around residue $A\beta$ K28 which can serve as an anchor for AChR binding through insertion into the acetylcholine binding site. Such anchoring and semi-induced fit is facilitated by the presence of 5 glycine residues of $A\beta$ which provide the necessary flexibility to undergo conformation changes. Interestingly, a PDB search for structures with glycine repeats every 4 residues, (GXXX)₄, like that found in $A\beta_{1-42}$ resulted in mostly α -helices that need to be tightly packed, flexible, and undergo secondary structure changes.

It is also interesting to note that even after oligomerization, $A\beta$ K28 of the ultimate $A\beta$ unit remains solvent accessible (Fig. 5), as if to retain the capacity of interacting with AChR and anchoring in the acetylcholine binding site. This is in line with a study by Lambert et al. which find $A\beta$ -derived diffusible ligands (ADDL) to be potent central nervous system neurotoxins (Lambert et al., 1998).

It is unclear, if $A\beta$ peptides are prone to undergo the conformational transition from α - to β -hairpins autonomously (Straub and Thirumalai, 2011), or if binding to AChR or $A\beta$ oligomers is required for lowering the energetic barrier between the conformation states (Dziewczapolski et al., 2009). Molecular dynamics predictions show that only small $A\beta$ segments can fold




Fig. 4. Predicted interaction of $A\beta$ in the AChR binding site. (A) Shown is $A\beta$ K28 which protrudes into the AChR binding site, and occludes acetylcholine binding. The ammonium group of $A\beta$ K28 forms cation/ π interaction with aromatic residues, α^7 Y115, α^7 W171, α^7 Y210, and α^7 Y217 lining the acetylcholine binding site. (B) Lysine (i.e. $A\beta$ K28) and acetylcholine are homologous in that they have a positively charged head linked through an aliphatic chain to a carbonyl tail.

into β -structures autonomously (Straub and Thirumalai, 2011), yet experimental evidence show that the $A\beta$ interaction with α^7 -AChR is crucial for AD progression (Dziewczapolski et al., 2009). In any case, it is safe to assume that the antiparallel β -sheet formed between $A\beta$ and the AChR lowers the energetic barrier for structural conversion of $A\beta$ peptides from α - to β -structure. With or without the assistance of AChR, $A\beta$ peptides are believed to zip together to form long β -hairpins. Such “zipping” mechanisms are common in protein structural conversions, and were postulated for polar zippers by Perutz (1995), steric zippers of amyloid-like fibrils (Nelson et al., 2005), and recently with β -sheet elongation of prion proteins (Samson and Levitt, 2011).

3.2. Similarities and differences of α -neurotoxins and $A\beta_{1-42}$

In this study we deal with the similarities of $A\beta_{1-42}$ and α -neurotoxins, however there are several differences too. For instance, α -neurotoxins bind AChR with nanomolar affinity while $A\beta_{1-42}$ binds AChR with picomolar affinity (Wang et al., 2000a,b; Samson et al., 2002). The large affinity differences arise from α -neurotoxins interacting through three “fingers” and a “tail”, whereas $A\beta_{1-42}$ interacts through one β -hairpin “finger” only. Also k_{on} of $A\beta_{1-42}$ is lower than that of snake toxins. This is because, unlike α -neurotoxins that are constrained by several disulfide bonds, $A\beta$ binding is conformation dependent. This illustrates the importance of the disulfide bonds in α -neurotoxins, without which binding would also be conformation dependent and less efficient. The disulfide bonds which rigidify the protein backbone skeleton also prevent the toxins from forming fibrils like $A\beta_{1-42}$ which is more flexible due to glycine repeats.




Fig. 5. AChR assists $A\beta$ folding into β -hairpins. Shown on the left are three structures of $A\beta$ peptides in equilibrium between the helix-kink-helix and α -hairpin conformations (PDB IDs 1IYT (Crescenzi et al., 2002), 1BA4 (Coles et al., 1998) and 1AML (Sticht et al., 1995)). Upon complex formation with the AChR, $A\beta$ K28 inserts into the acetylcholine binding site (see Fig. 4) and the α -hairpin becomes a β -hairpin through an induced fit mechanism driven by intermolecular β -sheet formation. Finally, the β -hairpins oligomerize into neurotoxic protofibrils (PDB ID 2BEG (Lührs et al., 2005)). Note that $A\beta$ K28 of the ultimate protofibril (or ADDL) monomer remains solvent accessible to bind the AChR, and that its β -strand can still form an intermolecular β -strand.

Table 4

Multiple sequence alignment of neuronal AChR α -subtypes and a high affinity peptide elicited against α -neurotoxins.

	123456789012
$\alpha 3$ -subtype (mouse)	IKYNCCEEIYQD
$\alpha 3$ -subtype (human)	IKYNCCEEIYPD
$\alpha 4$ -subtype (mouse)	RKYECCEIYPD
$\alpha 4$ -subtype (human)	RKYECCEIYPD
$\alpha 7$ -subtype (mouse)	KFYECCKEPYPD
$\alpha 7$ -subtype (human)	RFYECCKEPYPD
High affinity peptide	RYYESLSLEPYD
	:.. **

3.3. Similarities and differences of $\alpha 3$, $\alpha 4$, and $\alpha 7$ AChR subtypes

Our model shows the binding interactions of $A\beta_{1-42}$ with homopentameric human $\alpha 7$ AChRs, yet we believe that the same interactions apply to $\alpha 4\beta 2$ AChRs (Wu et al., 2004). The interactions are almost identical in both $\alpha 4$ and $\alpha 7$ because they are formed principally with the acetylcholine binding site and the peptide backbone of the AChR cys loop hairpin. These interactions explain well how AChRs are inhibited by amyloid peptides. In addition, the interactions also explain why the mouse $\alpha 4$ subtype bind $A\beta$ more effectively than mouse $\alpha 3$ and $\alpha 7$ in brain regions (Martin-Ruiz et al., 1999). The reason being that the mouse $\alpha 4$ subtype is more similar to the potent and high affinity peptides residues 1–4 (Scherf et al., 2001, 1997) elicited against α -neurotoxins than other mouse α -subunit types (Table 4). These four residues, 1–4, constitute the binding residues of the high affinity peptide with BTX. Intriguingly, for human AChR the contrary is expected, as the $\alpha 7$ -subtype is more similar to the high affinity peptide than $\alpha 3$ and $\alpha 4$ subtype residues 1–4. Our proposed model of the interaction of human nicotinic homopentameric $\alpha 7$ -AChR should thus serve as a general model for $A\beta_{1-42}$ interactions with AChRs.

3.4. High $A\beta_{1-42}$ levels reduce cognition

The reduced cognition in Alzheimer's patients is mainly due to neuronal death. Yet intriguingly, cognitive dysfunction is related to amyloid concentration as it has been seen in postoperative patients (Evered et al., 2009). This cognitive dysfunction could be due to the rise of free $A\beta$ oligomers (or ADDL) levels that inhibit cholinergic neurotransmission and induce a brain fog state. This is partially why prescription of acetylcholine esterase (AChE) inhibitors, such as neostigmine, is so beneficial in Alzheimer's patients as it elevates the effective acetylcholine agonist level, which competitively inhibit the $A\beta$ antagonist binding. Alzheimer's disease is a multifaceted disorder and most likely there are a number of complex pathological processes interacting or independent from amyloid processes, such as tau pathology and inflammation, that lead to clinical AD. We do not claim that amyloid binding to AChR is the sole mechanism for cognitive impairment, rather a contributory factor.

3.5. Potential AD therapies

Recently, Heinemann and coworkers showed that, despite the presence of high amounts of $A\beta$ deposits in the brain, deleting the $\alpha 7$ -AChR in mice models of AD lead to protection from dysfunction of learning and memory (Dziewczapolski et al., 2009). And so, disrupting the $A\beta_{1-42}$ interaction with $\alpha 7$ -AChR may represent a novel approach to reducing $A\beta_{1-42}$ -mediated toxicity in AD. This study provides a detailed molecular model for the interaction between $A\beta_{1-42}$ and $\alpha 7$ -AChR. Based on these interactions, two separate structure based therapies are currently underway in our

laboratory. One therapy involves blocking the $A\beta_{1-42}$ binding site on the $\alpha 7$ -AChR periphery (without blocking acetylcholine binding), and another entails blocking the $\alpha 7$ -AChR binding site on $A\beta_{1-42}$. In both cases, the therapies would block interactions of $A\beta_{1-42}$ with AChR and attenuate $A\beta$ -mediated neurotoxicity (Dziewczapolski et al., 2009). Attempts in this direction have been made, and peptides eliminating $A\beta$, such as PDB ID 20TK, were engineered (Hoyer et al., 2008). Interestingly, $A\beta$ of 20TK forms an intermolecular β -sheet with the hapten molecule similarly and in agreement to those formed with AChR of our model (data not shown). Unfortunately, these peptides are ineffective in the treatment of AD as they probably resolubilize $A\beta$. We suggest designing small $A\beta$ analogs that bind the segment $\alpha^7 F189$ – $\alpha^7 E191$ of AChR without protruding into the acetylcholine binding site. Such analogs are currently being designed in our lab.

These therapies should come in addition to proteolytic enzyme inhibitors that block the synthesis of $A\beta_{1-42}$ from APP, as well as acetylcholine esterase (AChE) inhibitors which function by increasing the level of available acetylcholine in the synapse, that can compete with $A\beta$.

This study is much needed in a time where Alzheimer research is trapped because of the lack of hypothesis that can explain the underlying pathophysiology. The amyloid hypothesis has been discredited after its failure to explain why plaque elimination does not improve the mental condition of Alzheimer's patient. The tau hypothesis alone cannot explain Alzheimer's disease on its own, and neither can apolipoprotein E. The scientific community is indeed in need of good alternative hypotheses that can explain the underlying biology responsible for the symptoms of Alzheimer's diseases.

Conflict of interest statement

None declared.

Acknowledgement

We wish to thank Prof. Michael Levitt for valuable comments.

References

- Brejck K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. *Nature* 2001;411(6835):269–76.
- Coles M, Bicknell W, Watson AA, Fairlie DP, Craik DJ. Solution structure of amyloid beta-peptide(1–40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? *Biochemistry* 1998;37(31):11064–77.
- Crescenzi O, Tomaselli S, Guerrini R, Salvadori S, D'Ursi AM, Temussi PA, et al. Solution structure of the Alzheimer amyloid beta-peptide (1–42) in an apolar microenvironment. Similarity with a virus fusion domain. *Eur J Biochem* 2002;269(22):5642–8.
- Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. *Trends Pharmacol Sci* 2004;25:317–24.
- De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. *Physiol Rev* 2000;90(2):465–94.
- Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF. Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. *J Neurosci* 2009;29(27):8805–15.
- Evered LA, Silbert BS, Scott DA, Maruff P, Laughton KM, Volitakis I, et al. Plasma amyloid beta42 and amyloid beta40 levels are associated with early cognitive dysfunction after cardiac surgery. *Ann Thorac Surg* 2009;88(5):1426–32.
- Hoyer W, Grönwall C, Jonsson A, Ståhl S, Hård T. Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. *Proc Natl Acad Sci U S A* 2008;105(13):5099–104.
- Kalamida D, Poulas K, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K, et al. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. *FEBS J* 2007;274(15):3799–845.
- Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. *Proc Natl Acad Sci U S A* 1998;95(11):6448–53.
- Le Novere N, Changeux JP. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. *J Mol Evol* 1995;40:155–72.

- Lee DH, Wang HY. Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1–40 and beta-amyloid1–42. *J Neurobiol* 2003;55(1):25–30.
- Lindstrom JM. In: North A, editor. *Hand book of receptors and channels: ligand- and voltage-gated ion channels*. Boca Raton, FL: CRC Press; 1995. pp. 153–75.
- Liu Q, Kawai H, Berg DK. beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. *Proc Natl Acad Sci U S A* 2001;98(8):4734–9.
- Lou X, Liu Q, Tu X, Wang J, Teng M, Niu L, et al. The atomic resolution crystal structure of atratoxin determined by single wavelength anomalous diffraction phasing. *J Biol Chem* 2004;279(37):39094–104.
- Lühns T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, et al. 3D structure of Alzheimer's amyloid-beta(1–42) fibrils. *Proc Natl Acad Sci U S A* 2005;102(48):17342–7.
- Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, et al. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. *J Neurochem* 1999;73(4):1635–40.
- Nagele RG, D'Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of beta-amyloid(1–42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. *Neuroscience* 2002;110(2):199–211.
- Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, et al. Structure of the cross-beta spine of amyloid-like fibrils. *Nature* 2005;435(7043):773–8.
- Perutz MF. Glutamine repeats as polar zippers: their role in inherited neurodegenerative disease. *Mol Med* 1995;1(7):718–21.
- Samson AO, Levitt M. Protein segment finder: an online search engine for segment motifs in the PDB. *Nucleic Acids Res* 2009;37(Database issue):D224–8.
- Samson AO, Levitt M. Normal modes of prion proteins: from native to infectious particle. *Biochemistry* 2011;50(12):2243–8.
- Samson A, Scherf T, Eisenstein M, Chill J, Anglister J. The mechanism for acetylcholine receptor inhibition by alpha-neurotoxins and species-specific resistance to α -bungarotoxin revealed by NMR. *Neuron* 2002;35(2):319–32.
- Scherf T, Balass M, Fuchs S, Katchalski-Katzir E, Anglister J. Three-dimensional solution structure of the complex of alpha-bungarotoxin with a library-derived peptide. *Proc Natl Acad Sci U S A* 1997;94(12):6059–64.
- Scherf T, Kasher R, Balass M, Fridkin M, Fuchs S, Katchalski-Katzir E. A beta-hairpin structure in a 13-mer peptide that binds alpha-bungarotoxin with high affinity and neutralizes its toxicity. *Proc Natl Acad Sci U S A* 2001;98(12):6629–34.
- Steinlein O. New functions for nicotine acetylcholine receptors? *Behav Brain Res* 1998;95:31–5.
- Sticht H, Bayer P, Willbold D, Dames S, Hilbich C, Beyreuther K, et al. Structure of amyloid A4-(1–40)-peptide of Alzheimer's disease. *Eur J Biochem* 1995;233(1):293–8.
- Straub JE, Thirumalai D. Toward a molecular theory of early and late events in monomer to amyloid fibril formation. *Annu Rev Phys Chem* 2011;62:437–63.
- Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 1994;22:4673–80.
- Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. beta-Amyloid(1–42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. *J Biol Chem* 2000a;275(8):5626–32.
- Wang HY, Lee DH, Davis CB, Shank RP. Amyloid peptide Abeta(1–42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. *J Neurochem* 2000b;75(3):1155–61.
- Wang HY, Li W, Benedetti NJ, Lee DH. Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. *J Biol Chem* 2003;278(34):31547–53.
- Wu J, Kuo YP, George AA, Xu L, Hu J, Lukas RJ. beta-Amyloid directly inhibits human alpha4beta2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. *J Biol Chem* 2004;279(36):37842–51.